MEDIPOST Co., Ltd. (KOSDAQ:078160)
South Korea · Delayed Price · Currency is KRW | Market Cap | 791.48B +163.2% |
| Revenue (ttm) | 73.66B +4.2% |
| Net Income | -85.40B |
| EPS | -2,408.00 |
| Shares Out | 39.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 122,067 |
| Average Volume | 258,267 |
| Open | 20,000 |
| Previous Close | 19,800 |
| Day's Range | 19,790 - 20,600 |
| 52-Week Range | 7,490 - 27,850 |
| Beta | 0.71 |
| RSI | 46.42 |
| Earnings Date | Apr 3, 2026 |
About MEDIPOST
MEDIPOST Co., Ltd. engages in the cord blood bank business in South Korea and internationally. The company operates through three divisions: Cord Blood Bank, Stem Cell Therapy, and Health Functional Food. It operates cord blood bank under the CELLTREE name. The company also offers CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis. In addition, it is developing stem cell products, such as PNEUMOSTEM for the preventative treatment of bronchopulmonary dysplasia. Further, the co... [Read more]
Financial Performance
In 2025, MEDIPOST's revenue was 73.66 billion, an increase of 4.25% compared to the previous year's 70.66 billion. Losses were -85.40 billion, 36.6% more than in 2024.
Financial StatementsNews
BDA Advises MEDIPOST on Growth Capital Raise
New York, NY December 18, 2025 --(PR.com)-- BDA Partners is pleased to announce that its client MEDIPOST, a leading stem cell therapeutics & cord blood banking biotech company in Korea, has raised g...